Curis Inc (CRIS) stock
CRISNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/3092% below fair value
$0.54+0.11 (+24.32%)
Close on Nov 17, 2026Market cap $1.13MP/E –Yield –
Curis operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Curis's operating income for the twelve months ending Jun 30, 2026 was -$8.76M. For fiscal 2025 it was -$5.71M. The highest annual figure on record is -$5.64M in fiscal 2010.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$5.71M | – |
| FY2024 | Dec 31, 2024 | -$44.54M | – |
| FY2023 | Dec 31, 2023 | -$48.33M | – |
| FY2022 | Dec 31, 2022 | -$53.02M | – |
| FY2021 | Dec 31, 2021 | -$42.07M | – |
| FY2020 | Dec 31, 2020 | -$24.90M | – |
| FY2019 | Dec 31, 2019 | -$24.36M | – |
| FY2018 | Dec 31, 2018 | -$29.33M | – |
| FY2017 | Dec 31, 2017 | -$49.76M | – |
| FY2016 | Dec 31, 2016 | -$58.04M | – |
| FY2015 | Dec 31, 2015 | -$56.48M | – |
| FY2014 | Dec 31, 2014 | -$15.86M | – |
| FY2013 | Dec 31, 2013 | -$9.42M | – |
| FY2012 | Dec 31, 2012 | -$18.62M | – |
| FY2011 | Dec 31, 2011 | -$7.20M | – |
| FY2010 | Dec 31, 2010 | -$5.64M | – |
| FY2009 | Dec 31, 2009 | -$10.04M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$9.94M | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.52M | – |
| Q4 FY2025 | Dec 31, 2025 | $19.62M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.92M | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.25M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.16M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.99M | – |
| Q3 FY2024 | Sep 30, 2024 | -$10.57M | – |
| Q2 FY2024 | Jun 30, 2024 | -$12.51M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.47M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.20M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.37M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.14M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.63M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.22M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.61M | – |
| Q2 FY2022 | Jun 30, 2022 | -$15.06M | – |
| Q1 FY2022 | Mar 31, 2022 | -$15.13M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.57M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.05M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.65M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.80M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.28M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.71M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.43M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.48M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.33M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.32M | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.14M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.56M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.15M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.42M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.86M | – |
| Q1 FY2018 | Mar 31, 2018 | -$9.91M | – |
| Q4 FY2017 | Dec 31, 2017 | -$7.13M | – |
| Q3 FY2017 | Sep 30, 2017 | -$14.47M | – |
| Q2 FY2017 | Jun 30, 2017 | -$13.11M | – |
| Q1 FY2017 | Mar 31, 2017 | -$15.05M | – |
| Q4 FY2016 | Dec 31, 2016 | -$10.76M | – |
| Q3 FY2016 | Sep 30, 2016 | -$27.79M | – |
See a number that looks wrong?